Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere

A technology of transforming growth factor and dexamethasone, which is applied in the fields of medical science and prostheses, can solve the problems that cannot be realized, achieve good tissue compatibility, reduce local inflammatory response, and reduce inflammatory effects

Inactive Publication Date: 2015-04-29
ZHEJIANG UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current mesh scaffold and fiber mesh c

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere
  • Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere
  • Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Preparation of TGF-β3 / DEX / PLGA microspheres with 6gPLGA

[0022] (1) Preparation of DEX / PLGA microspheres by water-oil-water (w / o / w) latex method: Take PLGA (6g), DEX (60mg) and dissolve it in 30ml of dichloromethane, and use a glass syringe (specification, 20G) Inject the mixed solution into 300ml of an aqueous solution containing 2% (w / v) polyvinyl alcohol (poly(vinyl alcohol, PVA), stir with a magnetic stirrer at 600rpm for 2-3 hours (35°C), and remove di Chloromethane, collect the microspheres after centrifugation at 1500rpm for 2min, wash with distilled water for 6 times, and freeze-dry for subsequent use;

[0023] (2) Production of heparin-TGF-β3 nanoparticles

[0024] Take heparin solution (0.5 mg / ml) and poly-L-lysine (0.5 mg / ml), dissolve it in distilled water (PH 7.4) 1:1 to form a 0.5 mg / ml solution, take 100 ng / ml TGF-β3 and add to 0.5 mg / ml heparin / poly-L-lysine solution, stirred continuously for 15s, and incubated at room temperature for 30m...

Embodiment 2

[0027] Example 2 : Make TGF-β3 / DEX / PLGA microspheres with 12g PLGA.

[0028] (1) Preparation of DEX / PLGA microspheres

[0029] Take PLGA (12g), DEX (120mg) and dissolve it in 60ml of dichloromethane, use a glass syringe (specification, 20G) to inject the mixed solution into 600ml of aqueous solution containing 2% (w / v) PVA, stir with a magnetic stirrer at 600rpm After 2-3 hours (35°C), dichloromethane was removed, and the microspheres were collected by centrifugation at 1500 rpm for 2 minutes, washed with distilled water for 6 times, and then freeze-dried for later use;

[0030] (2) Production of heparin-TGF-β3 nanoparticles

[0031]Take heparin solution (0.5 mg / ml) and poly-L-lysine (0.5 mg / ml), dissolve it in distilled water (PH 7.4) 1:1 to form a 0.5 mg / ml solution, take 100 ng / ml TGF-β3 and add to 0.5 mg / ml heparin / poly-L-lysine solution, stirred continuously for 15s, and incubated at room temperature for 30min; a mixture with a molar charge ratio in the range of 0-3.1...

Embodiment 3

[0034] Example 3 : Make TGF-β3 / DEX / PLGA microspheres with 24g PLGA.

[0035] (1) Preparation of DEX / PLGA microspheres

[0036] Take PLGA (24g), DEX (240mg) and dissolve it in 240ml of dichloromethane, use a glass syringe (specification, 20G) to inject the mixed solution into 1200ml of an aqueous solution containing 2% (w / v) PVA, stir with a magnetic stirrer at 600rpm After 2-3 hours (35°C), dichloromethane was removed, and the microspheres were collected by centrifugation at 1500 rpm for 2 minutes, washed with distilled water for 6 times, and then freeze-dried for later use;

[0037] (2) Production of heparin-TGF-β3 nanoparticles

[0038] Take heparin solution (0.5 mg / ml) and poly-L-lysine (0.5 mg / ml), dissolve it in distilled water (PH 7.4) 1:1 to form a 0.5 mg / ml solution, take 100 ng / ml TGF-β3 and add to 0.5 mg / ml heparin / poly-L-lysine solution, kept stirring for 15 seconds, and incubated at room temperature for 30 minutes;

[0039] (3) Production of TGF-β3 / DEX / PLGA mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a controlled-release polylactic acid-glycolic acid copolymer microsphere containing a dexamethasone transforming growth factor. A preparation method comprises the following steps: preparing a DEX/PLGA composite microsphere by a water-oil-water emulsion process; positively charging the polylactic acid-glycolic acid copolymer microsphere embedded with DEX through polyethyleneimine of which the surface is covered with positive charges, and mixing TGF-beta3 with a heparin/poly L-lysine solution to form a mixture of which the molar charge ratio is 0-3.15; and mixing TGF-beta3-embedded heparin/poly L-lysine nanoparticles with the PLGA microsphere embedded with the DEX, and covering to obtain the microsphere. The growth-promoting proliferation differentiation action of the growth factor and the anti-inflammatory action of the DEX are compounded; the inflammatory effects caused by a cell attachment carrier are reduced; the controlled-release polylactic acid-glycolic acid copolymer microsphere relatively adapts to cell attachment; the controlled-release polylactic acid-glycolic acid copolymer microsphere is nontoxic and harmless to a living body; a cell scaffold can be degraded by the living body after being treated, and can be used as a carrier for preparing a biological scaffold.

Description

Technical field [0001] The invention is a biological tissue engineering cell stent material, which involves the method of surface modification of biomass materials. It especially involves a controllable mitochromic acid-hydroxyl acid-hydroxyl acid-hydroxyl acid (TGF-β3) converted growth factor (TGF-β3).PLGA) Micro balls and preparation methods. Background technique [0002] Many research teams have used myeloplasmic cells or mesenchymal stem cell composite cell stents for research on intervertebral disc tissue projects.In the assessment of biological stent materials, solid -state and pre -molded cell stents include mesh brackets and fiber grids.However, when these cell stents are used to transplant cells, open incisions are required to be implanted in intervertebral discs, destroying the natural closed micro -environment of the intervertebral disc, so the defect is obvious.At the same time, this type of cell bracket is mostly agar, hyaluronic acid, etc., although harmless to biol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L27/48A61L27/54A61L27/58A61L27/50
Inventor 梁成振周校澎李方财陈其昕
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap